Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. [electronic resource]
Producer: 20080819Description: 166-70 p. digitalISSN:- 1557-9190
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Chemotherapy, Adjuvant -- economics
- Costs and Cost Analysis -- methods
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Humans
- Lymphoma, Follicular -- drug therapy
- Male
- Models, Biological
- Prednisone -- administration & dosage
- Remission Induction -- methods
- Rituximab
- Survival Rate
- United States
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.